Nanotechnology-Based Approaches to Alzheimer's Clinical DiagnosticsPublic Deposited
The bio-barcode assay is a nanotechnology-based method for capturing and detecting proteins. It shows extraordinary sensitivity in detecting certain antigens at extremely low concentrations, now without the use of the polymerase chain reaction (PCR). This assay uses disease identification biomarkers that cannot be used in the conventional assays of today. ADDLs are considered neurotoxins in Alzheimer’s disease (AD) pathogenesis. This discovery has led to many different methods to detect ADDLs in AD-diagnosed patients. One approach is to detect ADDLs in human plasma, which is more widely used clinically and easier to obtain than CSF. Here we will attempt to detect ADDLs in plasma samples from 16 patients — 8 with AD and 8 without the disease. The results show that many different protocols and methods must be employed to successfully detect ADDLs using the bio-barcode assay. While an efficient protocol must still be developed, this study helps to establish a new diagnostic approach for AD using the bio-barcode assay.